Aura Biosciences Presents Phase 2 Data on Bel-sar Treatment
![Aura Biosciences Presents Phase 2 Data on Bel-sar Treatment](https://investorshangout.com/images/blog/ihnews-Aura%20Biosciences%20Presents%20Phase%202%20Data%20on%20Bel-sar%20Treatment.jpg)
Aura Biosciences Presents Phase 2 Data at The Retina Society Annual Meeting
Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company focused on precision therapies for solid tumors, has announced its participation in The Retina Society Annual Meeting. The event is set to be held on September 11-15, where the company will present Phase 2 end of study data on the suprachoroidal administration of bel-sar. This treatment is aimed at patients with early-stage choroidal melanoma and indeterminate lesions.
Presentation Details
The presentation will highlight key results from a Phase 2 clinical trial, emphasizing the efficacy and safety aspects of bel-sar, also known as Belzupacap Sarotalocan (AU-011). The detailed session will be conducted by Dr. Ivana Kim, MD, affiliated with Mass Eye and Ear.
Title: Final Results of a Phase 2 Trial of Suprachoroidal Administration of Bel-sar for Choroidal Melanoma
Presenter: Dr. Ivana Kim, MD, Mass Eye and Ear
Date/Time: Thursday, September 12, from 11:04 am to 11:09 am Western European Daylight Time (6:04 am to 6:09 am Eastern Time)
A recording of the presentation will be accessible following the live session, ensuring that interested parties can revisit the findings and discussions.
Virtual Investor Event
In addition to the presentation, Aura Biosciences will host a virtual ocular oncology investor event featuring Dr. Kim and Dr. Prithvi Mruthyunjaya from Stanford University. During this session, they will delve into the Phase 2 end of study data and its implications on ocular oncology.
This investor event is scheduled for Thursday, September 12, at 8:00 am Eastern Time. It will include a live question and answer segment, encouraging interactions between the physicians and the attendees.
The webcast will also be available on Aura's website under the “Investors & Media” section, where it will remain accessible for 90 days post-event.
Expert Insights from Notable Presenters
Dr. Ivana K. Kim, MD, is prominent in the retina service at Mass Eye and Ear, where she addresses complex conditions such as retinal detachment and uveal melanoma. Dr. Kim also serves as Co-Director at the Harvard Ophthalmology AMD Center of Excellence, actively pushing the envelope in AMD treatment.
Her background includes significant training at Harvard Medical School and her extensive experience enhances the quality of care she provides and the research she leads?
Dr. Prithvi Mruthyunjaya, MD, MHS, serves as the Director of Ocular Oncology at Stanford University Byers Eye Institute. He is recognized for his dual expertise in ophthalmology and radiation oncology, and he is initiating research avenues for ocular cancer imaging and genetic studies.
Research Innovations by Aura Biosciences
Aura’s mission is to advance therapies that can preserve organ function while effectively treating cancer. Their lead candidate, bel-sar, is currently engaged in pivotal trials focused on primary choroidal melanoma and other ocular malignancies.
In parallel, there are explorations into bel-sar's utility in treating bladder cancer, underscoring the company's commitment to diversifying its therapeutic range. The ongoing global Phase 3 CoMpass trial is particularly significant as it aims to establish bel-sar as a first-line therapy option for adults with early-stage choroidal melanoma.
About Aura Biosciences
Aura Biosciences is at the forefront of biotechnology, transforming how solid tumors are treated. With an emphasis on precision therapies, the company is working on strategies to optimize survival rates and improve patient quality of life.
Headquartered in Boston, the company continues to make strides in ocular oncology and maintains a dynamic portfolio in clinical development. With a commitment to social visibility and engagement, Aura fosters connections through their online platforms.
Contact Information
For further inquiries, Alex Dasalla serves as the Head of Investor Relations and Corporate Communications. Interested parties can reach out via email at IR@aurabiosciences.com.
Frequently Asked Questions
What is the focus of the Phase 2 study presented by Aura Biosciences?
The Phase 2 study evaluates the efficacy and safety of suprachoroidal administration of bel-sar in treating early-stage choroidal melanoma.
Who are the key presenters for the upcoming event?
Dr. Ivana Kim and Dr. Prithvi Mruthyunjaya will present and discuss the findings at the Retina Society Annual Meeting and the virtual investor event.
How can I access the presentation details?
The presentation will be available online after the event, ensuring that the information can be accessed by those who missed the live session.
What is the significance of the bel-sar treatment?
Bel-sar aims to provide a vision-sparing therapy for patients with ocular melanoma, offering a potential alternative to traditional treatments that may compromise organ function.
Where can I find more information about Aura Biosciences?
More information about Aura and its innovative therapies can be found at their official website aurabiosciences.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Related Articles
- Pineapple Energy Reports Q2 Performance and Future Outlook
- The North West Company Inc. Q2 Results Conference Call Insights
- Paul Mueller Company Launches Major Expansion Project
- Impact of US Interest Rate Cuts on the Yuan
- Ecotourism Market Projections to Exceed USD 979 Billion by 2034
- Kidney Dialysis Market Set to Hit $149.7 Billion by 2033
- Lifecore Biomedical's 2024 Financial Performance Highlighted
- Micron Technology Faces Market Challenges Amid Price Cuts
- Geopolitical Risks Impact AI and Semiconductor Stocks
- Clear Blue Technologies Reports Strong Q2 2024 Results